Tandem Diabetes Care Inc. (NASDAQ:TNDM) shares fell to a low of $85.2975 before closing at $85.39. Intraday shares traded counted 0.52 million, which was 32.2% higher than its 30-day average trading volume of 771.32K. TNDM’s previous close was $85.65 while the outstanding shares total 62.45M. The firm has a beta of 0.20. The stock’s Relative Strength Index (RSI) is 50.19, with weekly volatility at 3.07% and ATR at 3.15. The TNDM stock’s 52-week price range has touched low of $75.26 and a $123.74 high. The stock traded lower over the last trading session, losing -0.30% on 05/28/21.
Investors have identified the Medical Devices company Tandem Diabetes Care Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $5.37 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Tandem Diabetes Care Inc. (TNDM) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 661.7 million total, with 103.41 million as their total liabilities.
TNDM were able to record 25.16 million as free cash flow during the 08/05/2021 quarter of the year, this saw their quarterly net cash flow reduce by 26.18 million. In cash movements, the company had a total of 28.68 million as operating cash flow.
Potential earnings growth for Tandem Diabetes Care Inc. (TNDM)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/05/2021 quarter of the year, Tandem Diabetes Care Inc. recorded a total of 141.04 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 30.57% coming in sequential stages and their sales for the 08/05/2021 quarter reducing by -19.16%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 67.75 million trying to sell their products during the last quarter, with the result yielding a gross income of 73.29 million. This allows shareholders to hold on to 62.45M with the recently reported earning now reading -0.08 cents per share. This is a figure that compared to analyst’s prediction for their 08/05/2021 (-0.07 cents a share).
Having a look at the company’s valuation, the company is expected to record 0.57 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TNDM sounds very interesting.
Is the stock of TNDM attractive?
In related news, Director, TWOMEY CHRISTOPHER J sold 269 shares of the company’s stock in a transaction that recorded on May 19. The sale was performed at an average price of 89.03, for a total value of 23,949. As the sale deal closes, the EVP, Chief Business/Compliance, BERGER DAVID B now sold 201 shares of the company’s stock, valued at 17,917. Also, Director, TWOMEY CHRISTOPHER J sold 4,802 shares of the company’s stock in a deal that was recorded on Apr 22. The shares were price at an average price of 95.00 per share, with a total market value of 456,190. Following this completion of acquisition, the Director, TWOMEY CHRISTOPHER J now holds 3,198 shares of the company’s stock, valued at 303,868. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.21%.
9 out of 17 analysts covering the stock have rated it a Buy, while 5 have maintained a Hold recommendation on Tandem Diabetes Care Inc.. 1 analysts has assigned a Sell rating on the TNDM stock. The 12-month mean consensus price target for the company’s shares has been set at $125.06.